

## **ROYALTY PHARMA TO PRESENT AT THE GOLDMAN SACHS 43<sup>RD</sup> ANNUAL GLOBAL HEALTHCARE CONFERENCE**

**NEW YORK, NY, June 8, 2022** – Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to present at the Goldman Sachs 43<sup>rd</sup> Annual Global Healthcare Conference on June 14, 2022 at 2:20 p.m. ET.

The webcast will be accessible from Royalty Pharma’s “Events” page at <https://www.royaltypharma.com/investors/news-and-events/events>. The webcast will also be archived for a minimum of thirty days.

### **About Royalty Pharma**

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on around 35 commercial products, including AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Johnson & Johnson’s Tremfya, Gilead’s Trodelvy, Merck & Co.’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and ten development-stage product candidates. For more information, visit [www.royaltypharma.com](http://www.royaltypharma.com).

### **Royalty Pharma Investor Relations and Communications**

+1 (212) 883-6772  
[ir@royaltypharma.com](mailto:ir@royaltypharma.com)

---